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QUESTION ASKED: Can a care model that uses a mul-
tidisciplinary clinic team and an electronic health re-
cord (EHR)-based risk assessment and communication
tool improve venous thromboembolism (VTE) education
and risk assessment rates in patients with cancer ini-
tiating outpatient cancer-directed therapy?
SUMMARY ANSWER: The Venous Thromboembolism
Prevention in the Ambulatory Cancer Clinic (VTE-
PACC) program sustainably increased VTE education
and risk assessment rates from , 5% to . 95% in
outpatients with cancer. The program identified 23% of
the total patient population as at high risk for VTE, and
94% of high-risk patients who received additional
evaluation and recommendations from a thrombosis
specialist elected to receive anticoagulant prophylaxis.
WHAT WE DID:We developed and deployed a model of
care in our outpatient oncology clinic that included
a role for nurses, advanced practice providers, phar-
macists, hematologists, oncologists, and the EHR. The
goal was to increase compliance with national
guidelines by educating all patients about VTE risk,
conducting a standardized VTE risk assessment, and
identifying patients at high risk for VTE. High-risk
patients were then offered patient-specific recom-
mendations (drug, dose, andduration) for anticoagulation
prophylaxis that included patient preferences.
WHAT WE FOUND: By using a team-based approach,
the VTEPACC model was successful in identifying,
educating, and treating patients with cancer at high
risk for VTE. High-risk patients were accepting of
a referral to discuss VTE prophylaxis options.
BIAS, CONFOUNDING FACTORS: The multidisciplinary
efforts of our team may not be able to be matched at
other institutions, limiting external validity. The VTE-
PACC model may require modifications based on
resource constraints at other oncology practices, in-
cluding non-EHR–based assessment tools and
communications.
REAL LIFE IMPLICATIONS: Our findings demonstrate
a feasible and effective approach that could be
adopted by other oncology practices to optimize VTE
education, risk assessment, and prophylaxis, and
meet national guidelines for prevention of cancer-
associated thrombosis.
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abstract
PURPOSE Guidelines recommend venous thromboembolism (VTE) risk assessment in outpatients with cancer
and pharmacologic thromboprophylaxis in selected patients at high risk for VTE. Although validated risk
stratification tools are available,, 10% of oncologists use a risk assessment tool, and rates of VTE prophylaxis in
high-risk patients are low in practice. We hypothesized that implementation of a systems-based program that
uses the electronic health record (EHR) and offers personalized VTE prophylaxis recommendations would
increase VTE risk assessment rates in patients initiating outpatient chemotherapy.
PATIENTS AND METHODS Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic (VTEPACC)
was a multidisciplinary program implemented by nurses, oncologists, pharmacists, hematologists, advanced
practice providers, and quality partners. We prospectively identified high-risk patients using the Khorana and
Protecht scores ($ 3 points) via an EHR-based risk assessment tool. Patients with a predicted high risk of VTE
during treatment were offered a hematology consultation to consider VTE prophylaxis. Results of the con-
sultation were communicated to the treating oncologist, and clinical outcomes were tracked.
RESULTS A total of 918 outpatients with cancer initiating cancer-directed therapy were evaluated. VTE monthly
education rates increased from, 5% before VTEPACC to 81.6% (standard deviation [SD], 11.9; range, 63.6%-
97.7%) during the implementation phase and 94.7% (SD, 4.9; range, 82.1%-100%) for the full 2-year
postimplementation phase. In the postimplementation phase, 213 patients (23.2%) were identified as be-
ing at high risk for developing a VTE. Referrals to hematology were offered to 151 patients (71%), with 141
patients (93%) being assessed and 93.8% receiving VTE prophylaxis.
CONCLUSION VTEPACC is a successful model for guideline implementation to provide VTE risk assessment and
prophylaxis to prevent cancer-associated thrombosis in outpatients. Methods applied can readily translate into
practice and overcome the current implementation gaps between guidelines and clinical practice.
JCO Oncol Pract 16:e868-e874. © 2020 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
Primary prevention of venous thromboembolism (VTE)
has been shown to be successful in ambulatory pa-
tients with cancer receiving chemotherapy, with an
average reduction in VTE rates of approximately
50%.1-6 National guidelines for VTE prophylaxis in
ambulatory patients with cancer recommend an in-
dividual patient risk assessment and targeted pro-
phylaxis for patients with cancer at the highest risk of
VTE7-9 because of the variable rates of reported bleed-
ing risk and the lack of a clear survival advantage.6,10
However, data from the Association of Community
Cancer Centers reported that only 9% of oncology
practitioners reported using a structured risk as-
sessment tool in the outpatient setting, and 44% of
practices reported , 10% of their outpatients with
cancer had clear documentation of VTE risk.10a A
successful model for guidelines implementation is
needed to increase VTE risk assessment and pre-
vention in patients with cancer.
VTE risk assessment models have been studied in
outpatients with cancer in an effort to identify the 10%-
20% of all patients with cancer most likely to develop
a VTE and benefit most from VTE prophylaxis.11,12 The
most well-studied and validated VTE risk assessment
tool was developed by Khorana et al13 and focuses
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on outpatients with cancer initiating chemotherapy. This risk
stratification tool assesses prechemotherapy WBC count,
hemoglobin and platelet count, body mass index, and tumor
type, and is recommended by the National Comprehensive
Cancer Network to identify patients with cancer at high risk
for VTE. Practical and evidence-based approaches for
implementing risk assessments and prophylaxis pre-
scribing in the oncology clinic are not available.
We report a multidisciplinary intervention, Venous Thrombo-
embolism Prevention in the Ambulatory Cancer Clinic (VTE-
PACC), designed to improve guideline adherence in
outpatients initiating cancer-directed therapy. Our approach
focused on integration into systems of practice, incorporation of
patient preferences, and inclusion of a multidisciplinary team.
OBJECTIVES
The aims of this project were to develop an effective model
to improve VTE education and risk assessment rates, and
increase the percentage of high-risk patients receiving
VTE prophylaxis using a novel multidisciplinary and elec-
tronic health record (EHR)-based program for guideline
implementation.
PATIENTS AND METHODS
VTEPACC was a prospective quality improvement research
initiative developed in collaboration with the Jeffords In-
stitute for Quality at the University of Vermont Medical
Center using a preimplementation and postimplementation
study design. The program was designed to provide VTE
education and risk assessment to all patients with cancer
initiating any cancer-directed therapy (chemotherapy,
targeted therapy, or immunotherapy) in the outpatient
setting at a single institution, the University of Vermont
Cancer Center. Institutional review board approval was
obtained (CHRMS 16-145) before initiation.
Patient eligibility was based on a histologic confirmation of
cancer that required initiation of cancer-directed therapy.
The therapy received by the patient was determined by the
treating oncologist. Patients with all malignancy types, in-
cluding lung, breast, head and neck, renal, pancreatic,
upper and lower GI, gynecologic, and urologic cancer, were
included. Patients with lymphoma were included; however,
patients with a hematologic malignancy, such as those with
leukemia, were excluded because therapy initiation was
generally in the inpatient setting. Patients at any stage of
disease requiring therapy were included; however, patients
with early-stage disease who received radiation therapy
only were not assessed as part of the VTEPACC program.
Patients were excluded if they (1) received hormonal
therapy only or (2) had a confirmed diagnosis of VTE at the
time of VTE risk assessment. Patients with brain tumors
were included at the time of study initiation and sub-
sequently were excluded after the initiation of an in-
vestigator clinical trial enrolling this patient group at our
institution. Patients who were receiving anticoagulation for
another medical reason (eg, atrial fibrillation) were included
in the initial risk assessment, as were patients receiving any
dose of aspirin therapy.
The VTEPACC program comprised 4 key structural com-
ponents (Fig 1), including (1) an EHR-based assessment
tool for bleeding and thrombosis risk to identify high-risk
patients with cancer for targeted VTE prophylaxis; (2) a data
capture and electronic reporting methodology; (3) an
electronic alert for referral to the thrombosis program for
high-risk patients; and (4) an EHR-based communication
tool to enhance physician and nursing communication,
that is, the Thrombosis Action Plan using EPIC EHR soft-
ware. The model is based on a multidisciplinary care team
including oncologists, hematologists, advanced practice
providers (APPs), nurses, and pharmacists (Table 1).
An overview of the VTEPACC care pathway is shown in
Figure 2. Outpatients with cancer coming to the ambulatory
cancer clinic for their initial treatment received both verbal
education and written material regarding VTE risk and signs
and symptoms of thrombosis by a nurse. An assessment of
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durg & duration of VTE
prophylaxis determined
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VTE education for
all patients
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assessment of bleeding &
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FIG 1. Elements of the Venous Throm-
boembolism Prevention in the Ambu-
latory Cancer Clinic Program. EHR,
electronic health record; VTE, venous
thromboembolism.
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VTE risk was performed by an oncology nurse using the
Khorana and Protecht scores built into the EHR. Patients
with a predicted high risk of VTE during treatment (defined
as $ 3 points on the Khorana or Protecht score) were
offered a hematology consultation, where patient-specific
VTE prophylaxis recommendations were made. Results of
the consultation, including individualized drug and dosing
recommendations, were electronically communicated to
the treating oncologist with the initial recommended pre-
scription written by the hematologist in a majority of pa-
tients. The Data Supplement contains examples of the
communication tool, Thrombosis Action Plan, and the
electronic risk assessment tool. Data quality monitoring,
education rates, risk assessment rates, and referral rates for
high-risk patients were reviewed monthly using electronic
data dashboards.
The primary quality outcomes were the number of patients
receiving VTE risk assessment and education, and number
of high-risk patients receiving VTE prophylaxis. Secondary
endpoints included number of patients accepting a refer-
ral to the thrombosis program. Ascertainment of VTE
education rates and risk assessment were captured via
a searchable function embedded within the risk assess-
ment flow sheet. This same tool also captured patient
preference with regard to thrombosis referral (yes/no) and
prior VTE history. The tool contains drop-down elements as
well as an automatic Khorana and Protecht score
calculator.
VTE education and risk assessment rates before VTEPACC
were based on chart review, and oncologists were also
queried directly regarding general practice patterns that
may not be captured in the chart to further verify the
preintervention rates. The primary clinical outcome of VTE
(pulmonary embolism of deep vein thrombosis) was based
on International Classification of Disease (10th revision)
codes (with validation of 20% of patients by chart review).
After a 1-year planning and preparation phase, there was
a 6-month implementation phase, where study metrics
were monitored, followed by a 2-year postimplementation
phase. Before the start of the implementation, all members
of the clinical and study team met monthly to prepare for
the project initiation. Monthly meetings of team members
TABLE 1. Members and Roles of a Multidisciplinary Clinical Team to Provide VTE Risk Assessment and Prophylaxis in Outpatients With Cancer
Team Member Role(s) Stage of Involvement
Primary oncology nurse Identifies patients initiating outpatient therapy Initiates intervention
Performs VTE risk assessment using electronic health record
Performs VTE signs and symptoms education for all patients
using standardized materials
Offers referral to thrombosis specialist for patients at high risk
for VTE
Places electronic referral
Oncology physician Cosigns initial electronic referral Initial involvement minimal
Receives Thrombosis Action Plan Receives completed recommendations and carries out plan
moving forwardContinues anticoagulation and anticoagulation monitoring
per Thrombosis Action Plan
Oncology APP Provides individualized bleeding and thrombosis risk
assessment during patient consultation and engages
patient in decision making
Engaged in individualized patient decision making and
assessment regarding VTE prophylaxis (yes/no) and therapy
choice after initial referral
Generates patient-specific action plan that is routed/
communicated to treating oncologist
Writes initial 1-month prescription for prophylactic
anticoagulation
Thrombosis physician
specialist/
hematologist
Provides individualized bleeding and thrombosis risk
assessment during patient consultation
Engaged in individualized patient decision making and
assessment regarding VTE prophylaxis (yes/no) and therapy
choice after initial referralSupports and assists APPs
Pharmacist Prepares assessment of potential drug interactions for
anticoagulation options available to patient before patient
visit
Prepares potential drug interaction assessment based on current
patient medication list before consultative appointment
Available to provide additional drug-specific information
directly to the patient
Can also be incorporated into individualized risk assessment
and recommendations with appropriate training
Abbreviations: APP, advanced practice provider; VTE, venous thromboembolism.
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were conducted as part of an iterative Plan-Do-Study-Act
process, continued throughout the project, and were in-
formed by updated dashboard metrics.
RESULTS
VTE Risk Assessment for Outpatients With Cancer
Initiating Therapy
A total of 918 sequential patients were evaluated during the
2-year postimplementation phase. VTE risk assessment
and education rates were , 5% before VTEPACC. During
the implementation phase, education and risk assessment
rates increased to 81.6% (range, 63.6%-97.7%) per month
and further to 94.7% (range, 82.1%-100%) per month for
the full 2-year postimplementation phase when all sys-
tems were in place (Fig 3). Based onmonthly teammeetings
that reviewed study metrics, program improvements were
made in the EHR documentation, new nurse onboarding
processes were implemented, and streamlining of the
thrombosis consult initiation was performed, triggered by
primary nursing. It was through this iterative process that
VTE education and risk assessment rates were able to
increase.
High-Risk Patients Receiving Anticoagulation Therapy
During the 2-year postimplementation period, a total of 213
outpatients with cancer (23.2%) initiating therapy were
found to be at high risk for developing a VTE. This pro-
portion remained stable over the duration of the reporting
period (6 2%). Of the high-risk patients, 70.9% were re-
ferred to a hematologist, pharmacist, or APP who was part
of the Thrombosis and Hemostasis Program, and 93.4% of
referred patients were subsequently assessed (eg, arrived
for the visit). Reasons for nonreferral included (1) the
patient was already on full-dose anticoagulation for another
reason, and (2) the patient refused referral. A common
barrier encountered that precluded the Thrombosis and
Hemostasis Program visit was the need for an additional
clinic visit; this barrier was successfully addressed later in
the implementation phase by offering visits that coincided
with chemotherapy infusion dates and times. For the high-
risk patients referred, 93.8% received personalized pro-
phylactic anticoagulation therapy (approximately half re-
ceived a prophylactic dose of a direct oral anticoagulant
[DOAC]), one third received a prophylactic dose of low
molecular weight heparin (LMWH), and the remainder
received unfractionated heparin and warfarin (, 3%).
VTE Rates in Outpatients With Cancer Initiating Therapy
on VTEPACC
The major clinical outcome tracked after VTEPACC initia-
tion was VTE in the first 6 months of therapy. Patients
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identified as being at high risk for VTE during initial risk
assessment had an 8.0% risk of VTE at 6months during the
2-year study phase. This compares with a VTE rate of
12.8% in the implementation phase. The VTE rate at
6 months in the study phase was 6.1% in the medium-risk
group and 2.1% in the low-risk group.
DISCUSSION
VTEPACC represents a successful guideline implementa-
tion initiative that includes a multidisciplinary team of on-
cologists, hematologists, APPs, pharmacists, and nurses,
and an EHR-based risk assessment that was nursing
driven. We substantially increased VTE education and risk
assessment rates and achieved a high thromboprophylaxis
rate in patients who were found to be at high risk for VTE.
Outpatients with cancer initiating therapy were accepting
of a thrombosis referral that involved an individual risk
assessment and discussion of both thrombosis and bleed-
ing risk, and the majority of these patients received VTE
prophylaxis.
The difficulty in meeting guidelines for outpatients with
cancer nationwide to improve VTE prophylaxis underscores
the need to develop successful models of care delivery.
Guidelines recommend the use of a validated risk assess-
ment tool to distinguish high- versus low-risk patients.7,8,14
Both the Khorana risk score and Protecht score are vali-
dated tools to assess this risk, and a prior study found that
use of a computerized system that assessed elements of
the Khorana score found in the EHR was effective in
identifying high-risk patients.15 However, additional guid-
ance regarding implementation, guided individualized de-
cision making, and choice of anticoagulant is missing. We
hypothesized that at least 1 component that contributed to a
lack of guideline implementation was the lack of expertise in
anticoagulation drugs as well as bleeding and thrombosis risk
assessment. We addressed this through a multidisciplinary
approach using thrombosis experts to guide oncologists
and patients regarding anticoagulant options as well as
pharmacists to assess drug-drug interactions. In addition,
VTEPACC emphasized a consistent and central role for
nursing to effectively deploy the program. We analogized
VTE risk assessment and education to neutropenic fever
risk assessment and education at our oncology clinic. This
approach accurately reflects the real risks of subse-
quent hospitalization, morbidity, and death, and resulted in
. 95% of patients receiving guideline-recommended care.
Recent guidelines have expanded the number of drug
options (apixaban, rivaroxaban, or LMWH) for primary
prophylaxis in high-risk patients with cancer.14 Primary
prophylaxis with LMWH reduces the risk of symptomatic
VTE in outpatients with cancer treated with chemotherapy.6
Direct oral anticoagulants are also effective. In the AVERT
trial (Apixaban for the Prevention of Venous Thromboem-
bolism in High-Risk Ambulatory Cancer Patients) among
intermediate- to high-risk patients (Khorana score $ 2),
a significant reduction in VTE was seen in the apixaban
group (4.2%) compared with the group receiving placebo
(10.2%; hazard ratio, 0.41)16. Rivoraxaban efficacy in the
primary prevention of a combined endpoint of symptomatic
and asymptomatic VTE was also suggested in the CASSINI
trial (Rivoraxaban for Preventing Venous Thromboembo-
lism in High-Risk Ambulatory Patients With Cancer) in
patients with a Khorana score$ 2 initiating cancer-directed
therapy.17 In both trials, an increase in bleeding was seen
mitigating some of the benefits of treatment. Given these
findings, systems of care that incorporate both thrombosis
and bleeding risk as well as individualized patient prefer-
ence are a necessity. In the VTEPACC model, 50% of
patients received DOAC prophylaxis, and pharmacy eval-
uation for drug interactions with both DOAC and LMWH
were performed. We also observed that DOACs had the
lowest number of drug interactions18.
The principal goal of thromboprophylaxis is VTE prevention
in subgroups of patients who will most benefit. In the
clinical trial setting, VTE occurred in 11% of high-risk
patients receiving placebo in a study of nadroparin pro-
phylaxis and 10.2% of placebo patients in the AVERT trial
(Khorana score$ 2).16,19 A recent systematic review found
the 6-month incidence of VTE was 11% in patients with
a Khorana score$ 3.20 In the VTEPACC population, the rate
of VTE at 6 months from study initiation was 12.8% and was
approximately 40% lower, at 8.2% after full implementation
of VTEPACC. These results support VTEPACC as effective in
reducing VTE in a real-world setting.
The prospective evaluation and treatment of a large
number of consecutive patients in this outpatient cohort
allows for applicability of our study results to patients with
cancer initiating therapy in the outpatient setting. Themajor
limitation of this study is the single-center design. The
applicability to smaller practices is not known, and a per-
ceived barrier could be the lack of hematologists, although
a large number of patients in VTEPACC were seen by APPs
trained in thrombosis and bleeding related to patients with
cancer, and in subsequent work, we are assessing the
impact of pharmacist-driven patient consultations. In ad-
dition, education and risk assessment rates may not
account for all patients because the ability to capture
appropriate patients via the EHR across all clinics and
treatment regimens was challenging.
The effectiveness of a multidisciplinary approach to ad-
dress VTE risk assessment and prophylaxis in oncology
patients underscores the need for leveraging multiple areas
of expertise to optimize clinical outcomes. Implementation
of VTEPACC using a multidisciplinary team and EHR-based
approach improved VTE risk assessment and education.
VTEPACC was successfully able to identify patients at high
risk for developing a VTE and offer personalized VTE
prophylaxis. Successful implementation of guidelines to
prevent cancer-associated thrombosis could have a sig-
nificant impact on patient morbidity and mortality.
e872 © 2020 by American Society of Clinical Oncology Volume 16, Issue 9
Holmes et al
Downloaded from ascopubs.org by 74.103.217.93 on November 4, 2020 from 074.103.217.093
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
AFFILIATIONS
1Department of Medicine, University of Vermont Cancer Center,
University of Vermont, Burlington, VT
2MD Anderson Cancer Center, Houston, TX
3Spectrum Health Lakeland, St Joseph, MI
4Department of Medicine, University of Vermont, Burlington, VT
5College of Pharmacy, University of Rhode Island, Kingston, RI
6Data Management Office, University of Vermont Health Network,
Burlington, VT
CORRESPONDING AUTHOR
Chris E. Holmes, MD, PhD, Department of Medicine, Hematology and
Oncology Division, 111 Colchester Ave, Given Building, Second Fl,
University of Vermont, Burlington, VT 05401; e-mail: ceholmes@
uvm.edu.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if
applicable) are available with this article at DOI https://doi.org/10.1200/
JOP.19.00697.
AUTHOR CONTRIBUTIONS
Conception and design: Chris E. Holmes, Steven Ades, Susan Gilchrist,
Daniel Douce, Britny Rogala, Mary Cushman, Allison Kaigle Holm
Administrative support: Allison Kaigle Holm
Provision of study materials or patients: Emily Parenteau, Karen Libby,
Chris Holmes, Steven Ades, Mary Cushman
Collection and assembly of data: Chris E. Holmes, Steven Ades, Karen
Libby, Mary Cushman, Allison Kaigle Holm
Data analysis and interpretation: Chris E. Holmes, Steven Ades, Susan
Gilchrist, Daniel Douce, Britny Rogala, Mary Cushman, Allison
Kaigle Holm
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
ACKNOWLEDGMENT
The authors thank additional and past members of the project team,
including Jacob Barker, Jordan Tolstoi, Katie Michaud, Kate Devine,
Yongli Ji, and Mike Gianni.
REFERENCES
1. Agnelli G, Gussoni G, Bianchini C, et al: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced
solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943-949, 2009
2. Riess H, Pelzer U, Deutschinoff G, et al: A prospective, randomized trial of chemotherapy with or without the lowmolecular weight heparin (LMWH) enoxaparin
in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. J Clin Oncol 27, 2009 (abstr LBA4506)
3. Maraveyas A, Waters J, Roy R, et al: Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48:1283-1292, 2012
4. Akl EA, Gunukula S, Barba M, et al: Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.
Cochrane Database Syst Rev (4):CD006652, 2011
5. Akl EA, Schünemann HJ: Routine heparin for patients with cancer? One answer, more questions. N Engl J Med 366:661-662, 2012
6. Di Nisio M, Porreca E, Candeloro M, et al: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane
Database Syst Rev 12:CD008500, 2016
7. Farge D, Debourdeau P, Beckers M, et al: International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients
with cancer. J Thromb Haemost 11:56-70, 2013
8. Lyman GH, Bohlke K, Falanga A: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical
practice guideline update. J Oncol Pract 11:e442-e444, 2015
9. Key NS, Bohlke K, Falanga A: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update summary.
J Oncol Pract 15:661-664, 2019
10. Thein KZ, Yeung S-CJ, Oo TH, et al: Risk of bleeding from primary thromboprophylaxis (PTP) in patients with solid cancer receiving chemotherapy: A
systematic review and meta-analysis of randomized controlled trials (RCT). Blood 128:3820, 2016
10a. Association of Community Cancer Centers: Venous Thromboembolism. Identifying Cancer Patients at Risk, 2016. https://www.accc-cancer.org/docs/projects/
resources/pdf/vte-identifying-cancer-patients-at-risk-2016
11. Streiff MB: Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients. Clin Adv Hematol Oncol 11:
349-357, 2013
12. Connolly GC, Francis CW: Cancer-associated thrombosis. Hematology (Am Soc Hematol Educ Program) 2013:684-691, 2013
13. Khorana AA, Kuderer NM, Culakova E, et al: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:
4902-4907, 2008
14. Key NS, Khorana AA, Kuderer NM, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.
J Clin Oncol 38:496-520, 2019
15. Lustig DB, Rodriguez R, Wells PS: Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in
ambulatory cancer patients at intermediate-high risk for venous thrombosis. Thromb Res 136:1099-1102, 2015
16. Carrier M, Abou-Nassar K, Mallick R, et al: Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380:711-719, 2019
17. Khorana AA, Soff GA, Kakkar AK, et al: Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380:720-728, 2019
18. Ng H, Rogala B, Ades S, et al: Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation. J Oncol
Pharm Practice 2020 DOI: 10.1177/1078155220901569
19. Verso M, Agnelli G, Barni S, et al: A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The
Protecht score. Intern Emerg Med 7:291-292, 2012
20. Mulder FI, Candeloro M, Kamphuisen PW, et al: The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and
meta-analysis. Haematologica 104:1277-1287, 2019
n n n
JCO Oncology Practice e873
Successful Model for VTE Guideline Implementation
Downloaded from ascopubs.org by 74.103.217.93 on November 4, 2020 from 074.103.217.093
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer
Clinic
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted.
Relationships are self-held unless noted. I5 Immediate Family Member, Inst5My Institution. Relationships may not relate to the subject matter of this manuscript.
For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Susan Gilchrist
Consulting or Advisory Role: Outcomes4Me
Britny Rogala
Speakers’ Bureau: Genentech
Mary Cushman
Research Funding: Sphingotech (Inst)
No other potential conflicts of interest were reported.
e874 © 2020 by American Society of Clinical Oncology Volume 16, Issue 9
Holmes et al
Downloaded from ascopubs.org by 74.103.217.93 on November 4, 2020 from 074.103.217.093
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
